← back to search

Yu-Jui Ho

Research Center for Environmental Changes, Academia Sinica · US
Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Genomics and Diagnostics, Pancreatic and Hepatic Oncology Research, Immune cells in cancer, and Cancer Immunotherapy and Biomarkers.
h-index
34
citations
9,001
works
238
NIH funding
primary concept
Biology
email

Recent publications

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
Cell 2026cited by 1position: middledoi
Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition
Cell 2026cited by 1position: middledoi
α-Ketoglutarate dehydrogenase is a therapeutic vulnerability in acute myeloid leukemia
Blood 2025cited by 14position: middledoi
A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma
Cancer Discovery 2025cited by 13position: middledoi
SMAD4 induces opposite effects on metastatic growth from pancreatic tumors depending on the organ of residence
Nature Cancer 2025cited by 5position: middledoi
Stromal KITL/SCF Maintains Pancreas Tissue Homeostasis and Restrains Tumor Progression
Cancer Discovery 2025cited by 3position: middledoi
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
Nature Aging 2024cited by 174position: middledoi
Interferon Epsilon Loss Is Elusive 9p21 Link to Immune-Cold Tumors, Resistant to Immune Checkpoint Therapy, and Endogenous CXCL9/10 Induction
Journal of Thoracic Oncology 2024cited by 10position: middledoi
Author Correction: Senolytic CAR T cells reverse senescence-associated pathologies
Nature 2024cited by 8position: middledoi
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer
eLife 2024cited by 2position: middledoi
Timing of treatment shapes the path to androgen receptor signaling inhibitor resistance in prostate cancer
eLife 2024cited by 1position: middledoi
STING inhibits the reactivation of dormant metastasis in lung adenocarcinoma
Nature 2023cited by 225position: middledoi
Epigenetic plasticity cooperates with cell-cell interactions to direct pancreatic tumorigenesis
Science 2023cited by 202position: middledoi
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance
Nature Cancer 2023cited by 108position: middledoi
MLL3 regulates the CDKN2A tumor suppressor locus in liver cancer
eLife 2023cited by 20position: middledoi
Ordered and deterministic cancer genome evolution after p53 loss
Nature 2022cited by 232position: middledoi
Senescence Rewires Microenvironment Sensing to Facilitate Antitumor Immunity
Cancer Discovery 2022cited by 220position: middledoi
Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer
Nature Medicine 2022cited by 143position: middledoi
Base editing sensor libraries for high-throughput engineering and functional analysis of cancer-associated single nucleotide variants
Nature Biotechnology 2022cited by 128position: middledoi
MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis
Nature Cancer 2022cited by 117position: middledoi
Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer
Proceedings of the National Academy of Sciences 2022cited by 87position: middledoi
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade
Journal of Clinical Investigation 2022cited by 25position: middledoi
A preclinical platform for assessing antitumor effects and systemic toxicities of cancer drug targets
Proceedings of the National Academy of Sciences 2022cited by 14position: middledoi
Epigenetic plasticity cooperates with emergent cell-cell interactions to drive neoplastic tissue remodeling in the pancreas
bioRxiv (Cold Spring Harbor Laboratory) 2022cited by 6position: middledoi
Ogdh Is a Genetic Vulnerability and Therapeutic Target in Acute Myeloid Leukemia
Blood 2022cited by 3position: middledoi
A gene–environment-induced epigenetic program initiates tumorigenesis
Nature 2021cited by 318position: middledoi
Senolytic CAR T cells reverse senescence-associated pathologies
Nature 2020cited by 1,020position: middledoi
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Cell 2020cited by 412position: middledoi
A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma
Nature Cancer 2020cited by 202position: middledoi
Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer
Cancer Cell 2020cited by 156position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Scott W. Lowe · Memorial Sloan Kettering Cancer Center28 papers (2018–2025)John P. Morris · UNC Lineberger Comprehensive Cancer Center10 papers (2018–2026)Direna Alonso‐Curbelo · Institute for Research in Biomedicine10 papers (2020–2026)Chi-Chao Chen · Howard Hughes Medical Institute9 papers (2018–2025)Elisa de Stanchina · European Molecular Biology Laboratory9 papers (2018–2025)Sha Tian · Hospital for Special Surgery9 papers (2018–2025)Francisco M. Barriga · Centro de Investigación Biomédica en Red de Cáncer9 papers (2020–2025)Timour Baslan · University of Pennsylvania8 papers (2018–2025)Amanda Kulick · West Virginia University8 papers (2018–2025) · 8 papers (2021–2025)Josef Leibold · STZ eyetrial7 papers (2018–2024)Alexandra Wuest · Massachusetts Institute of Technology7 papers (2022–2025)Francisco J. Sánchez‐Rivera · Howard Hughes Medical Institute7 papers (2018–2023)Richard P. Koche · New York Proton Center6 papers (2019–2025)Dana Pe’er · Howard Hughes Medical Institute6 papers (2021–2025)Ronan Chaligné · Memorial Sloan Kettering Cancer Center6 papers (2022–2026)Janelle Simon · Kettering University6 papers (2020–2025)John E. Wilkinson · Cold Spring Harbor Laboratory6 papers (2020–2025)Kaloyan M. Tsanov · Memorial Sloan Kettering Cancer Center6 papers (2020–2025)Riccardo Mezzadra · Oncode Institute6 papers (2020–2025)